The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Evolution of Proteomic Profiles of Intestinal Microbiota in Patients With Locally Advanced or Metastatic Urothelial Carcinomas
Official Title: Analysis of the Evolution of Proteomic Profiles of Intestinal Microbiota in Patients With Locally Advanced or Metastatic Urothelial Carcinomas According to Their Response to Immunotherapy (Responders vs. Non-responders) : A Prospective Pilot Study
Study ID: NCT04566029
Brief Summary: Immunotherapy has become an essential therapeutic weapon against many cancers. Control point inhibitors (CPI, PD-1/PD-L1) have shown efficacy in the therapeutic management of tumors in the bladder in progression after administering platinum derivatives. But only 20% of patients get any clinical benefit from these heavy treatments in the long term. Treating metastatic patients without distinction means taking a considerable risk of toxicity and generates major costs. It is therefore urgent and important to exceed the current criteria for using immunotherapy. Recent studies have shown the interest of studying intestinal microbiota as a marker of the efficacy of immunotherapy. The investigators hypothesized that the proteomic signature of the intestinal microbiota in patients with locally advanced or metastatic urothelial carcinomas who responded to immunotherapies was special, and has very different characteristics from that of patients with the same pathology who do not respond to immunotherapy.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
ICM parc euromedecine, Montpellier, Hérault, France
Hopital Tenon ( Paris), Paris, Paris Cx 20, France
Institut Sainte Cancerologie Lucien Neuwirth, Avignon, Saint Priest En Jarez, France
ICO-Site Paul Papin, Angers, , France
Institut Bergonié, Bordeaux, , France
Centre Leon Berard, Lyon, , France
Centre Antoine Lacassagne, Nice, , France
HEGP GH Universitaire Paris Ouest, Paris, , France
ICANS Strasbourg, Strasbourg, , France
Iuct Oncopole, Toulouse, , France